A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy

The June quarter demonstrated IHL’s ability to execute on a multi-channel development strategy. For medicinal cannabinoid and psychedelic pharmaceutical company Incannex Healthcare (ASX:IHL), Q4 marked a busy quarter as it made a number of key research advancements across its multi-channel product suite. And in its quarterly filing this morning, the company highlighted the latest developments as it pursues six different US Food and Drug Administration programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.   Psilocybin treatment Among IHL’s treatment studies is its “Psi-GAD” combination therapy that…

A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy Topshelf News.

source https://topshelf.news/a-busy-q4-shows-how-incannex-healthcare-is-laying-the-foundations-for-its-clinically-backed-global-growth-strategy/